Editor's Note: The 2023 Chinese Congress on Holistic Integrative Oncology (CCHIO), organized by the China Anti-Cancer Association and hosted by Tianjin Medical University Cancer Hospital, will take place in Tianjin from November 16th to 19th, 2023. This conference will continue to uphold the theme of "Cancer Prevention and Control: Success through Integration," attracting anti-cancer experts and professionals from around the world to share cutting-edge academic achievements. "Oncology Frontier" had the special opportunity to interview Professor Ji-Hui Hao from Tianjin Medical University Cancer Hospital, the Executive Director of the conference and the hosting institution, to gain a deeper understanding of the new CCHIO.
Oncology Frontier: The China Cancer Congress (CCO) has been held for over twenty years. This year, it is being held for the first time under the name CCHIO. What do you think this change reflects the development of oncology and cancer prevention in China?
Professor Ji-Hui Hao: In 2018, the China Cancer Congress first introduced the concept of "Cancer Prevention and Control: Success through Integration," which continues to influence and guide the development of oncology in China. This year, the CCO returns to Tianjin and is officially renamed as the CCHIO, signaling that holistic treatment has transitioned from subtle daily practice to the forefront, enriching it with a more profound meaning. The transformation from CCO to CCHIO reflects the multidisciplinary development of oncology in China, emphasizing the shift in cancer diagnosis and treatment from simple disease management to comprehensive, all-rounded, and holistic patient care throughout the entire treatment process. This change also reflects the gradual shift in cancer prevention and control in China towards high quality, and precision, placing greater emphasis on disease prevention, early screening, accurate diagnosis, and individualized treatment. In terms of research cooperation, we actively engage in international collaboration and integrating global research resources. Through exchanges and collaborations with international peers, we aim to learn from and absorb advanced international research results and experiences to promote the progress of oncology in China. Simultaneously, China's influence and voice in the field of oncology continue to grow on the international stage. As we progress, we reciprocate by contributing to the global anti-cancer cause, steadily improving the global level of cancer treatment. This year's CCHIO conference is not only the beginning of international holistic oncology but also a brilliant epitome of the concept of "Cancer Prevention and Control: Success through Integration" that has influenced and guided us for many years.
Oncology Frontier: Under the theme "Cancer Prevention and Control: Success through Integration," how should clinical practice, basic research, and translational research in pancreatic cancer in China be integrated and developed?
Professor Ji-Hui Hao: Pancreatic cancer is insidious in onset, highly malignant, and has a high mortality rate, traditionally holding the title of "king of cancers." According to the latest epidemiological data from the National Cancer Center, there are approximately 100,000 new cases of pancreatic cancer in China each year, ranking 10th among new malignant tumors. The annual death toll is 88,000, ranking 6th, posing a significant threat to the health of the Chinese people. In recent years, with a deepening understanding of the basic research, clinical research, and clinical practice of pancreatic cancer, we have made rich progress in the pathogenesis of pancreatic cancer, the identification of prognosis markers, the development of target therapies, and the exploration of immunotherapy Whether at this conference or in our daily research and clinical work, "Cancer Prevention and Control: Success through Integration" serves as the guiding compass for the diagnosis and treatment of pancreatic cancer.
In both research and clinical practice, basic research forms the theoretical foundation for the diagnosis and treatment of pancreatic cancer. Clinical practice validates the ethics of diagnosing and treating pancreatic cancer, while translational therapy bridges the gap between the two. The organic integration of these three aspects will effectively elevate the level of pancreatic cancer treatment. At the level of basic research, collaboration between hospitals and basic research institutions, as well as close cooperation between researchers and clinical doctors, should be encouraged to share research findings and experiences and explore potential mechanisms. In translational research, collaboration among hospitals, enterprises, research institutions, and others to jointly verify new diagnostic and treatment technologies will facilitate the rapid maturation of potential treatment strategies. In the clinical aspect, a multidisciplinary collaborative treatment model will provide patients with more comprehensive and personalized treatment plans. On this basis, rigorous validation of new theories and strategies will broaden the horizons for the treatment of pancreatic cancer.
Oncology Frontier: The CACA guidelines leverage the "Belt and Road" initiative to reach out internationally, and you and your team have published research results in internationally renowned conferences and journals. Please share how Chinese research and development in the diagnosis and treatment of pancreatic cancer should be promoted internationally, and how to amplify the voice of China on the global stage.
Professor Ji-Hui Hao: Even on a global scale, the incidence of pancreatic cancer is on the rise each year, and its high mortality rate poses a significant challenge to patient survival. In the context of building a community of shared future for humanity, any progress made by any group or individual will contribute to improving the overall treatment of pancreatic cancer worldwide. Our team's research and clinical work in pancreatic cancer have received international attention and recognition. This is closely linked to the support of the country, associations, hospitals, and the hard work of the team. Showcasing China's research and development achievements in the diagnosis and treatment of pancreatic cancer to international peers and amplifying the voice of China is an embodiment of China's soft power. First, it is necessary to strengthen international cooperation by establishing extensive cooperative relationships with international peers through participation in international conferences and collaborative research, jointly conducting research and exchanges on pancreatic cancer. For example, at this year's CCHIO, we have set up an international venue, bringing together over 100 international speakers, which will greatly promote exchanges and mutual learning. Second, it is important to further refine and promote Chinese experiences. In 2023, we formulated the "China Anti-Cancer Association Integrative Diagnosis and Treatment Guidelines for Pancreatic Cancer," providing crucial guidelines for the diagnosis and treatment of pancreatic cancer. Transforming China's diagnostic and treatment standards and experiences into internationally accepted language and standards and promoting China's experiences and achievements through participation in international diagnostic and treatment guidelines, and textbook writing will help provide reference and inspiration for global pancreatic cancer diagnosis and treatment, enabling international peers to draw from China's experiences and practices. Third, continuous improvement of China's research capabilities in the field of pancreatic cancer, especially in basic and translational research, will help enhance China's research and innovation capabilities in the field of pancreatic cancer. This will contribute to making a more significant contribution to global pancreatic cancer diagnosis and treatment. In summary, building a community of shared future for humanity cannot be achieved without the voice of China.
Oncology Frontier: Can you share your message for the upcoming CCHIO conference?
Professor Ji-Hui Hao: After 17 years, CCO returns as CCHIO, and for the first time, it adopts the "1+N" model with Tianjin as the main venue and 31 provincial and municipal sub-venues. This will be the largest academic annual conference organized by the China Anti-Cancer Association. CCHIO serves as a window and platform for China to showcase its academic achievements globally, as well as a new ground for domestic and international oncology academic exchanges. During the conference, we will actively and closely promote international cooperation, expand exchanges with high-level international academic institutions, strengthen inter-hospital collaboration and talent development, integrate global anti-cancer forces, and drive the development of China's anti-cancer efforts. Together, we aim to create a better future for all of humanity in the fight against cancer and work towards building a community of shared destiny. We wish the 2023 CCHIO a resounding success.